Dividend Stock Analysis: Does Eli Lilly Have Enough Promise in Its Pipeline?
The Dividend Pig submits:Eli Lilly (LLY) and Company discovers, develops, manufactures and sells pharmaceutical products. It also has an animal health business segment. Its products are sold in approximately 125 countries worldwide, and include such popular drugs as Cymbalta and Zyprexa. Sales, Earnings, and Free Cash Flow
Years Revenue (in millions)
Over the past decade LLY has grown revenues by an average of 7.9%, and this number has accelerated over the past 5 year period, where revenue growth averaged 10.1%. 2010 saw an increase of 5.7% over 2009, where worldwide sales grew from 21.4 billion to 23 billion. With some major patent expirations coming up in the next few years, LLY has been focusing on three key areas for revenue growth - Japan, key emerging markets, and Elanco, it's animal health business.
- Japan has had strong growth over the past 2 years, gaining
Complete Story »